Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, as ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

If confirmed as health secretary, Robert F. Kennedy Jr. would oversee the Food and Drug Administration and other agencies ...

In a contentious confirmation hearing to become the nation’s top health official, Robert F. Kennedy Jr. struggled to answer ...

President Donald Trump’s nominee to run the Department of Health and Human Services, Robert F. Kennedy Jr., was in the hot ...

Tanzania President, Namibia President Elect and Merck Foundation Chief Executive Officer (CEO) named amongst 100 Most ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Oosthuizen increased their investment in Merck & Co by purchasing 8,664 shares through ...

Disclosed in the latest SEC filing, a significant insider purchase on January 29, involves Chirfi Guindo, Chief Marketing Officer at Merck & Co MRK.